https://www.zonebourse.com/cours/action/FORESEE-PHARMACEUTICALS-C-45304233/actualite/Foresee-Pharmaceuticals-annonce-le-dosage-du-premier-patient-dans-l-etude-clinique-de-phase-3-Caspp-45058315/?utm_source=telegram&utm_medium=social&utm_campaign=share